OCUMENSION THERAPEUTICS

Insiders Ocumension Therapeutics

Equities

1477

KYG674111011

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 14/05/2024 pm IST			5-day change	1st Jan Change
6.98 ^HKD	0.00%		-2.65%	+4.49%

15/04	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
15/04	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12	MT
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023	29/23/29	CI
Ocumension Therapeutics Announces Executive Changes	15/22/15	CI
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee	08/22/08	CI
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee	31/22/31	CI
Ocumension Therapeutics Announces Re-Designation of Executive Directors as Non-Executive Directors	20/21/20	CI
Ocumension Therapeutics Announces Board Changes	19/21/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW